Citizens Maintains Market Outperform on Avalo Therapeutics, Lowers Price Target to $55
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Citizens analyst Jason N. Butler maintains Avalo Therapeutics (NASDAQ:AVTX) with a Market Outperform and lowers the price target from $62 to $55.
Citizens analyst Jason N. Butler maintains Avalo Therapeutics (NASDAQ:AVTX) with a Market Outperform and lowers the price target from $62 to $55.